InMode (INMD) Company Overview

InMode Ltd. (NASDAQ:INMD ) Q4 2024 Results Conference Call February 4, 2025 8:30 AM ET Company Participants Miri Segal - CEO, MS-IR Moshe Mizrahy - Chief Executive Officer Michael Kreindel - Chief Technology Officer Yair Malca - Chief Financial Officer Rafael Lickerman - Vice President, Finance Conference Call Participants Danielle Antalffy - UBS Matt Miksic - Barclays Michael Sarcone - Jefferies Caitlin Cronin - Canaccord Genuity Mike Matson - Needham & Company Jeff Johnson - Baird Sam Eiber - BTIG Operator Good day, and welcome to the InMode Fourth Quarter and Full Year 2024 Earnings Results Conference Call.

YOKNEAM, Israel , Feb. 3, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that Yair Malca, Chief Financial Officer will host investor meetings at the BTIG MedTech, Digital Health, Life Sciences & Diagnostics Tools Conference in Snowbird, UT on Wednesday, February 12, 2025.

InMode Ltd. boasts superior fundamentals, yet trades at undervalued market multiples due to its unique risk profile. The company is a leader in the global aesthetics market with proprietary RF-based technologies. InMode's robust balance sheet and high profit margins support a substantial margin of safety at current prices, despite risks.

Conference call rescheduled to Tuesday, February 4, 2025, at 8:30 a.m. Eastern Standard Time YOKNEAM, Israel, Jan. 16, 2025 /PRNewswire/ -- InMode Ltd.

I'm downgrading InMode from a 'Strong Buy' to a 'Buy' due to consistent guidance cuts and short-term demand issues. Despite recent performance issues and high interest rates, INMD still holds a strong cash position, has high margins, and offers a good long-term entry point with a solid earnings yield. The company's revenue forecasts for 2024 and 2025 have been lowered notably, indicating potential market saturation and weak demand.

Conference call to be held on Thursday, February 6, 2025, at 8:30 a.m. Eastern Standard Time YOKNEAM, Israel, Jan. 8, 2025 /PRNewswire/ -- InMode Ltd.

InMode Ltd. demonstrates impressive net income growth from non-invasive surgical products, with new platforms Define and Envision expected to drive future business growth. The company's innovative technologies in plastic surgery, dermatology, gynecology, and ophthalmology, along with ongoing stock repurchases, make InMode a compelling buy. Strong financials show consistent income growth and significant cash flow, with minimal liabilities, indicating a robust financial position and undervaluation.

YOKNEAM, Israel , Nov. 6, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced the participation at the following investor conferences in November and December: UBS Global Healthcare Conference Presenters: Yair Malca, Chief Financial Officer Format: In-person fireside chat moderated by Danielle Antalffy, Senior Equity Analyst, and one-on-one meetings Location: Palos Verdes, CA When: Tuesday, Nov. 12 at 2:00 pm PT A live webcast of the presentation can be accessed here.

InMode's products are part of the medical aesthetics industry that is expected to grow at an 11% CAGR over the next five years. Despite a punishing macro environment of late that has seen its share price decline over 80% from its peak, InMode has remained profitable while continuing to innovate. The strong new and second-hand sales market for their platforms suggest their customers continue to see value in their products.